However, the FDA’s approval of nivolumab plus chemotherapy for first-line advanced gastric cancer did not mandate PD-L1 testing (FDA, 2025), meaning many patients with low PD-L1 expression (CPS<5) may receive a treatment not specifically suited for them. Here, CD274 is linked to gastric cancer.